TY  - JOUR
AU  - González-Alonso, Paula
AU  - Zazo, Sandra
AU  - Martín-Aparicio, Ester
AU  - Luque, Melani
AU  - Chamizo, Cristina
AU  - Sanz-Álvarez, Marta
AU  - Minguez, Pablo
AU  - Gómez-López, Gonzalo
AU  - Cristóbal, Ion
AU  - Caramés, Cristina
AU  - García-Foncillas, Jesús
AU  - Eroles, Pilar
AU  - Lluch, Ana
AU  - Arpí, Oriol
AU  - Rovira, Ana
AU  - Albanell, Joan
AU  - Piersma, Sander R
AU  - Jimenez, Connie R
AU  - Madoz-Gúrpide, Juan
AU  - Rojo, Federico
PY  - 2020
DO  - 10.3390/cancers12051108
SN  - 2072-6694
UR  - http://hdl.handle.net/20.500.12105/9932
AB  - Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - Hippo pathway
KW  - TEAD
KW  - YAP1
KW  - Anti-receptor therapy
KW  - Breast cancer
KW  - Resistance
KW  - Trastuzumab
TI  - The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
TY  - journal article
ER  -